Novartis’ Pluvicto Wins FDA Approval for Earlier Prostate Cancer Treatment
SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...
PSMA PET
Advertisement
Telix Completes Phase 3 Enrollment for Illuccix in Japan
MELBOURNE, Australia, and TOKYO, Japan, July 17, 2026 Telix Pharmaceuticals has completed patient enrollment in its pivotal Phase 3...
Clarity Signs Deal to Boost Prostate Cancer Imaging Supply
Sydney, Australia | April 14, 2026 Clarity Pharmaceuticals has announced the signing of a Commercial Manufacturing Agreement with Nucleus...
SECuRE Trial: Undetectable Disease With 67Cu-SAR-bisPSMA
SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...
Advertisement
